Henrik Hellquist1, Christopher A French2, Justin A Bishop3, Andrés Coca-Pelaz4, Evan J Propst5, António Paiva Correia6, Bo-Yee Ngan7, Ronald Grant8, Nicole A Cipriani9, David Vokes10, Rui Henrique11, Fernando Pardal12, Jose Ramon Vizcaino13, Alessandra Rinaldo14, Alfio Ferlito14. 1. Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal. 2. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 3. Departments of Pathology and Otolaryngology - Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 4. Department of Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain. 5. Department of Otolaryngology - Head and Neck Surgery, Hospital for Sick Children, University of Toronto, Toronto, Canada. 6. University Hospital of South Manchester NHS Foundation Trust, Manchester, UK. 7. Division of Pathology, Department of Pediatric Laboratory Medicine, Hospital for Sick Children, University of Toronto, Toronto, Canada. 8. Division of Hematology/Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, Canada. 9. Department of Pathology, The University of Chicago Medicine and Biological Sciences, Chicago, IL, USA. 10. Department of Otolaryngology - Head and Neck Surgery, Auckland City Hospital and Department of Surgery, University of Auckland, Auckland, New Zealand. 11. Department of Pathology, Portuguese Institute of Oncology, Porto, Portugal. 12. Anatomic Pathology Department, Braga Hospital, Braga, Portugal. 13. Anatomic Pathology Department, St Antonio General Hospital, Porto Hospitals Centre, Porto, Portugal. 14. University of Udine School of Medicine, Udine, Italy.
Abstract
AIMS: NUT midline carcinoma (NMC) is a rare undifferentiated and aggressive carcinoma that locates characteristically to the midline of the head and neck, and mediastinum. NMC is characterized by chromosomal rearrangements of the gene NUT, at 15q14. The BRD4 gene on 19q13 is the most common translocation partner forming a fusion oncogene, BRD4-NUT. By the end of 2014, the International NUT Midline Carcinoma Registry had 48 patients treated for NMC. Laryngeal NMC are exceedingly rare, and we report a case series of seven cases. METHODS AND RESULTS: We searched for cases in files of different hospitals as well as a thorough search of the English language literature. The diagnosis of NMC is made by demonstration of NUT rearrangement either by immunohistochemistry, fluorescence in-situ hybridization (FISH) or reverse transcription-polymerase chain reaction (RT-PCR). We found three previously published cases, and in this series add four cases of our own. CONCLUSIONS: NMC consists of monomorphic, often discohesive, cells with an epithelioid appearance and distinct nucleoli. The tumours typically show abrupt squamous differentiation. The mean age of the patients was 34 years, hence significantly lower than that for conventional laryngeal carcinoma. All tumours were located in the supraglottis and five patients died of the disease after 3, 7, 8, 9 and 11 months. Laryngeal NMC may be underdiagnosed, and an increased awareness among pathologists is warranted. NMC has characteristic morphological features, and positive immunostaining with the NUT antibody is diagnostic. Its aggressive behaviour demands a very intense treatment strategy and the need for its recognition is emphasized further by new promising treatment strategies.
AIMS: NUT midline carcinoma (NMC) is a rare undifferentiated and aggressive carcinoma that locates characteristically to the midline of the head and neck, and mediastinum. NMC is characterized by chromosomal rearrangements of the gene NUT, at 15q14. The BRD4 gene on 19q13 is the most common translocation partner forming a fusion oncogene, BRD4-NUT. By the end of 2014, the International NUT Midline Carcinoma Registry had 48 patients treated for NMC. Laryngeal NMC are exceedingly rare, and we report a case series of seven cases. METHODS AND RESULTS: We searched for cases in files of different hospitals as well as a thorough search of the English language literature. The diagnosis of NMC is made by demonstration of NUT rearrangement either by immunohistochemistry, fluorescence in-situ hybridization (FISH) or reverse transcription-polymerase chain reaction (RT-PCR). We found three previously published cases, and in this series add four cases of our own. CONCLUSIONS: NMC consists of monomorphic, often discohesive, cells with an epithelioid appearance and distinct nucleoli. The tumours typically show abrupt squamous differentiation. The mean age of the patients was 34 years, hence significantly lower than that for conventional laryngeal carcinoma. All tumours were located in the supraglottis and five patients died of the disease after 3, 7, 8, 9 and 11 months. Laryngeal NMC may be underdiagnosed, and an increased awareness among pathologists is warranted. NMC has characteristic morphological features, and positive immunostaining with the NUT antibody is diagnostic. Its aggressive behaviour demands a very intense treatment strategy and the need for its recognition is emphasized further by new promising treatment strategies.
Authors: Nicolas Reynoird; Brian E Schwartz; Manuela Delvecchio; Karin Sadoul; David Meyers; Chandrani Mukherjee; Cécile Caron; Hiroshi Kimura; Sophie Rousseaux; Philip A Cole; Daniel Panne; Christopher A French; Saadi Khochbin Journal: EMBO J Date: 2010-07-30 Impact factor: 11.598
Authors: Christopher A French; Jeffery L Kutok; William C Faquin; Jeffrey A Toretsky; Cristina R Antonescu; Constance A Griffin; Vania Nose; Sara O Vargas; Mary Moschovi; Fotini Tzortzatou-Stathopoulou; Isao Miyoshi; Antonio R Perez-Atayde; Jon C Aster; Jonathan A Fletcher Journal: J Clin Oncol Date: 2004-10-15 Impact factor: 44.544
Authors: Christopher A French; Isao Miyoshi; Ichiro Kubonishi; Holcombe E Grier; Antonio R Perez-Atayde; Jonathan A Fletcher Journal: Cancer Res Date: 2003-01-15 Impact factor: 12.701
Authors: Herbert Haack; Laura A Johnson; Christopher J Fry; Katherine Crosby; Roberto D Polakiewicz; Edward B Stelow; Seung-Mo Hong; Brian E Schwartz; Michael J Cameron; Mark A Rubin; Martin C Chang; Jon C Aster; Christopher A French Journal: Am J Surg Pathol Date: 2009-07 Impact factor: 6.394
Authors: C A French; C L Ramirez; J Kolmakova; T T Hickman; M J Cameron; M E Thyne; J L Kutok; J A Toretsky; A K Tadavarthy; U R Kees; J A Fletcher; J C Aster Journal: Oncogene Date: 2007-10-15 Impact factor: 9.867
Authors: Artyom A Alekseyenko; Erica M Walsh; Xin Wang; Adlai R Grayson; Peter T Hsi; Peter V Kharchenko; Mitzi I Kuroda; Christopher A French Journal: Genes Dev Date: 2015-07-15 Impact factor: 11.361
Authors: Lazar Tosic; Stefanos Voglis; Anna Maria Reuss; Elisabeth Jane Rushing; Luca Regli; Carlo Serra Journal: Acta Neurochir (Wien) Date: 2021-11-20 Impact factor: 2.216